

ANESTHESIOLOGY GRAND ROUNDS

Provided by Rutgers NJMS, Department of Anesthesiology



“Anesthetic Considerations for Patients with Neurologic Symptoms of Long Covid”

MSB B-552 & via Webex
12-4-2024 / 7:00am to 8:00am
Alex Bekker, MD, PhD
Professor & Chair
Department of Anesthesiology
Rutgers NJMS

Objectives

At the conclusion of this activity, participants should be better able to:

- Identify the indications/contraindications for new modalities in the diagnosis and treatment of conditions presented at each session.
- Describe new management and prevention strategies used for selected medical problems and types of patients.
- Discuss new developments and/or techniques being used in current scientific research.

Target Audience

This activity is designed for anesthesiologists, residents, and fellows in the administration of / management of complications related to anesthesia.

Accreditation



In support of improving patient care, Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians: Rutgers Biomedical and Health Sciences designates this live activity for a maximum of 1 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Declarations

Alex Bekker, MD, PhD has no relevant financial relationships with ineligible companies to disclose.

Speakers are required to disclose discussion of off-label/investigational uses of commercial products/devices in their presentation. These disclosures will be made to the audience at the time of the activity.

Planning Committee: Alex Bekker, MD, PhD and George Tewfik, MD, MBA have no relevant financial relationships with ineligible companies to disclose.

Rutgers Health CE Staff: Patrick Dwyer and Elizabeth Ward have no relevant financial relationships with ineligible companies to disclose.